Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Targeting a protein to treat acute myeloid leukaemia in children
Dr Karen Keeshan is researching to see if removing or blocking a specific protein involved in acute myeloid leukaemia can help make it easier to treat.
Studying immune cells to help develop new treatments for babies with leukaemia
Dr Samanta Mariani and her team want to understand more about the role immune cells play to help develop new ways to treat leukaemia in babies.
Looking for early signs on brain MRIs that can predict whether young people with ependymoma will go on to experience cognitive problems
Professor Shivaram Avula will identify markers in the brains of young people with brain tumours that will help predict the development of long-term side effects like learning and memory problems.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Making CAR-T cells that can rest to improve their cancer-fighting ability
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.